The Role of Probiotic LH76 in Human Gut Health
ConditionGut Microbiota Modulation
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorWecare Probiotics Co., Ltd.
About this trial
This study aims to evaluate the safety and efficacy of the probiotic LH76 as a dietary supplement in healthy adults. The research will assess its effects on gut microbiota composition, intestinal health, and immune function compared to a placebo. Key outcomes include changes in microbial diversity, intestinal barrier integrity, and immune response markers over the intervention period. The findings will contribute to understanding the potential health benefits of LH76 and its role in supporting gut and immune health.
Eligibility criteria
Qualifiers
Willing to undergo 3 follow-up visits during the intervention period Be willing to provide blood, urine and stool samples 2 times during the intervention period
Willing to self-administer probiotic or placebo once a day during the intervention period
Good eyesight, can read and write, can wear glasses
Have good hearing and be able to hear and understand all instructions during the intervention
Disqualifiers
Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor, prolonged coma - not including general anaesthesia)
Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia, psychosis, bipolar disorder
Take medication for depression or low mood Internal organ failure (heart, liver or kidney failure, etc.)
Trial design
Treatments tested in this trial
- probiotic LH76
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov